Peringkat dalam Saham
#2843
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops... CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Kapitalisasi Pasar
$6.96B
Perubahan (1 tahun)
210.23%
Perdagangan CG Oncology Inc. (CGON)
Harga CGON dengan kapitalisasi pasar B
Kapitalisasi pasar dari CG Oncology Inc.(CGON)
Kapitalisasi Pasar: $6.96B
Per August 2026, CG Oncology Inc. memiliki kapitalisasi pasar sebesar $6.96B. Ini menjadikan CG Oncology Inc. sebagai perusahaan 2843rd paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar CG Oncology Inc. dari 2024 hingga 2026
CGON dibandingkan dengan 5 teratas stocks paling populer
| Harga CGON |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.152T
|
+73,976.74%
|
|
|
|
|
$4.537T
|
+65,128.25%
|
|
|
|
|
$4.169T
|
+59,831.04%
|
|
|
|
|
$3.642T
|
+52,265.67%
|
|
|
|
|
$2.805T
|
+40,222.92%
|
